Spyre Therapeutics, Inc. (3920)
XDUS
71.50
-7.50 (-9.49%)
Closed
Oct 7, 2026
Day's Range
70.0072.00
52 wk Range
13.5094.00
Financial Statements - 3920 - Spyre Therapeutics, Inc.
Revenue
0
Net Income
-155.20M▲ 11.9%
EBITDA
-229.56M▼ 30.0%
Free Cash Flow
-169.25M▼ 27.0%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 886K | 2.32M | 18.73M | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -219.56M | -176.57M | -128.56M | -84.78M | -65.64M | -81.48M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 39.45M | -17.53M | -216.39M | -7K | -122K | -5K |
| Pre Tax Income | -155.21M | -176.06M | -338.81M | -83.95M | -65.66M | -80.89M |
| Income Tax | -15K | 43.17K | -26K | -136K | 141K | 0 |
| Net Income | -155.20M | -176.10M | -338.79M | -83.81M | -65.80M | -80.89M |
| EPS Basic | -1.98 | -3.18 | - | - | - | - |
| EPS Diluted | -1.98 | -3.18 | - | - | - | - |
| Basic Shares Outstanding | 64.05M | 39.81M | - | - | - | - |
| Diluted Shares Outstanding | 64.05M | 39.81M | - | - | - | - |
| Ebit | -219.56M | -176.57M | -128.56M | -84.78M | -65.64M | -81.48M |
| Ebitda | -229.56M | -176.57M | 69.44M | -83.21M | -64.07M | -80.48M |
| Net Income Continuous Operations | -155.20M | -176.10M | -338.79M | -83.81M | -65.80M | -80.89M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
